A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Survival in neonatal medicine has shown a steady improvement in recent years and, consequently, outcome measures in clinical trials have increasingly focused on quantifying neurodevelopmental impairment. However, whilst survival rates are improving, mortality is still significant in neonates requiring intensive care. This raises the question of how to account for deaths in clinical trials where neurodevelopmental impairment is the primary focus. This review details some of the approaches thatdoi:10.1136/archdischild-2014-306730 pmid:25605619 fatcat:3qhoighmsnaudhw3l7izxznzvi